DFTX (Definium Therapeutics) Tariff Resilience Score: 6/10 (As of Jun. 30, 2026)


DFTX Definium Therapeutics Inc DFTX
32 GF Score
Price $47.04
! 5 Warning Signs
View Full Analysis

What is Definium Therapeutics Tariff Resilience Score?

Definium Therapeutics DFTX +1.07% 32 Tariff Resilience Score is 6 as of Jun. 30, 2026. GuruFocus rates DFTX with a GF Score™ of 32/100. The stock has 5 warning signs investors should review. Among 1,375 Biotechnology companies, Definium Therapeutics ranks better than 76% on this metric.

Definium Therapeutics has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Definium Therapeutics has Mind Medicine, a biotech firm, faces moderate tariff risks due to its reliance on international supply chains for research materials. However, its focus on the U.S. market and potential for alternative suppliers provide some mitigation.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Definium Therapeutics might have Average Resilient.

Definium Therapeutics  (NAS:DFTX) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Definium Therapeutics Tariff Resilience Score Related Terms

DFTX vs LGND, XENE, CGON: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Definium Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Definium Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Definium Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Definium Therapeutics's Tariff Resilience Score falls into.


DFTX
32GF Score
Definium Therapeutics Inc DFTX
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Definium Therapeutics (DFTX) has a Tariff Resilience Score of 6 as of Jun. 30, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Definium Therapeutics ranks #330 out of 1375 companies in the Biotechnology industry, placing it in the top 24%.
Is Definium Therapeutics' Tariff Resilience Score too high?
Definium Therapeutics' current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Definium Therapeutics' value of 6 is 50% above this industry median. Based on the distribution chart, Definium Therapeutics ranks #330 out of 1375 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Definium Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Definium Therapeutics' Tariff Resilience Score compare to LGND and XENE?
According to the Biotechnology industry distribution chart, Definium Therapeutics ranks #330 out of 1375 companies for Tariff Resilience Score. This places Definium Therapeutics in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Definium Therapeutics' value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,375 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Definium Therapeutics's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Definium Therapeutics's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Definium Therapeutics stock overvalued right now?
Definium Therapeutics (DFTX) has a current Tariff Resilience Score of 6. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Definium Therapeutics' overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Definium Therapeutics (DFTX), the current Tariff Resilience Score is 6 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Definium Therapeutics Business Description

Other Exchanges MMQ0:Germany
Address One World Trade Center, Suite 8500, New York, NY, USA, 10007
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
32GF Score

Get the complete analysis for DFTX

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$47.04
Price